ISSN:
1573-0646
Keywords:
phase II
;
piroxantrone
;
non-small cell
;
lung cancer
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Conclusions Piroxantrone demonstrated no activity in 17 eligible patients. Toxicity was acceptable and dose escalations were performed. With only 35% (6/17) of patients experiencing grade 2 or greater granulocytopenia the study might be criticized for utilizing a less than optimal dose of piroxantrone. Based on this trial, piroxantrone is not felt to have significant antitumor activity against advanced non-small cell carcinoma of the lung.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF01275476
Permalink